Rigel Pharmaceuticals (RIGL) Surpasses Q4 Earnings and Revenue Estimates

Group 1 - Rigel Pharmaceuticals reported quarterly earnings of $0.80 per share, exceeding the Zacks Consensus Estimate of $0.55 per share, and compared to break-even earnings per share a year ago, representing an earnings surprise of 45.45% [1] - The company posted revenues of $57.6 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 0.02%, and this is an increase from year-ago revenues of $35.79 million [2] - Rigel shares have increased approximately 33% since the beginning of the year, while the S&P 500 has declined by 0.5% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is $0.31 on revenues of $44.8 million, and for the current fiscal year, it is $1.28 on revenues of $201.14 million [7] - The Zacks Industry Rank indicates that the Medical - Drugs sector is currently in the bottom 46% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8] Group 3 - The estimate revisions trend for Rigel is favorable, leading to a Zacks Rank 1 (Strong Buy) for the stock, indicating expected outperformance in the near future [6] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]